Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAI NASDAQ:KOD NASDAQ:OCS NASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Beckley$7.18+0.6%$4.77$3.06▼$7.22$2.63B1.5621.86 million shs10.97 million shsKODKodiak Sciences$41.92-1.2%$36.87$5.59▼$47.84$2.65B2.19817,770 shs435,383 shsOCSOculis$11.43-4.4%$16.32$10.52▼$34.47$693.49M0.44380,628 shs293,100 shsVERAVera Therapeutics$36.06-3.0%$37.10$19.07▼$56.05$2.67B0.922.60 million shs1.12 million shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Beckley+0.56%+33.96%+77.28%+50.52%+103.40%KODKodiak Sciences-1.18%-1.18%+14.44%-7.28%+651.25%OCSOculis-4.43%-12.88%-2.06%-57.30%-35.17%VERAVera Therapeutics-2.99%-15.15%-6.17%-6.07%+61.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Beckley$7.18+0.6%$4.77$3.06▼$7.22$2.63B1.5621.86 million shs10.97 million shsKODKodiak Sciences$41.92-1.2%$36.87$5.59▼$47.84$2.65B2.19817,770 shs435,383 shsOCSOculis$11.43-4.4%$16.32$10.52▼$34.47$693.49M0.44380,628 shs293,100 shsVERAVera Therapeutics$36.06-3.0%$37.10$19.07▼$56.05$2.67B0.922.60 million shs1.12 million shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Beckley+0.56%+33.96%+77.28%+50.52%+103.40%KODKodiak Sciences-1.18%-1.18%+14.44%-7.28%+651.25%OCSOculis-4.43%-12.88%-2.06%-57.30%-35.17%VERAVera Therapeutics-2.99%-15.15%-6.17%-6.07%+61.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIAtai Beckley 2.33Hold$11.3858.54% UpsideKODKodiak Sciences 2.63Moderate Buy$42.140.53% UpsideOCSOculis 2.80Moderate Buy$38.33235.37% UpsideVERAVera Therapeutics 2.77Moderate Buy$84.58134.56% UpsideCurrent Analyst Ratings BreakdownLatest OCS, KOD, VERA, and ATAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026ATAIAtai Beckley Berenberg BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$7.457/20/2026ATAIAtai Beckley Berenberg BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/20/2026ATAIAtai Beckley HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$25.00 ➝ $7.507/17/2026ATAIAtai Beckley TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold7/17/2026OCSOculis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026VERAVera Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026ATAIAtai Beckley JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold7/16/2026ATAIAtai Beckley Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$10.00 ➝ $7.507/16/2026ATAIAtai Beckley GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral7/16/2026ATAIAtai Beckley Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/16/2026ATAIAtai Beckley Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 7/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIAtai Beckley$4.09M646.32N/AN/A$0.69 per share10.41KODKodiak SciencesN/AN/AN/AN/A$2.97 per shareN/AOCSOculisN/AN/AN/AN/A$4.08 per shareN/AVERAVera TherapeuticsN/AN/AN/AN/A$8.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIAtai Beckley-$660.05M-$2.23N/AN/AN/A-19,019.44%-89.79%-63.58%8/13/2026 (Estimated)KODKodiak Sciences-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%8/12/2026 (Estimated)OCSOculis-$119.44M-$2.13N/AN/AN/A-8,460.67%-56.78%-45.62%8/6/2026 (Estimated)VERAVera Therapeutics-$299.61M-$5.54N/AN/AN/AN/A-74.86%-60.18%8/4/2026 (Estimated)Latest OCS, KOD, VERA, and ATAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026ATAIAtai Beckley-$0.10N/AN/AN/A$0.11 millionN/A8/12/2026Q2 2026KODKodiak Sciences-$0.97N/AN/AN/AN/AN/A8/6/2026Q2 2026OCSOculis-$0.48N/AN/AN/A$0.23 millionN/A8/4/2026Q2 2026VERAVera Therapeutics-$1.60N/AN/AN/A$1.28 millionN/A5/12/2026Q4 2025ATAIAtai Beckley-$0.11-$0.08+$0.03-$0.08$0.22 million$0.95 million5/8/2026Q1 2026OCSOculis-$0.49-$0.63-$0.14-$0.61$0.25 million$0.26 million5/7/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/A5/7/2026Q1 2026VERAVera Therapeutics-$1.3284-$1.69-$0.3616-$1.69$0.43 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATAIAtai BeckleyN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIAtai BeckleyN/AN/AN/AKODKodiak SciencesN/A3.543.54OCSOculis0.015.185.18VERAVera Therapeutics0.1513.6413.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIAtai Beckley28.41%KODKodiak Sciences89.06%OCSOculis22.30%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipATAIAtai Beckley19.80%KODKodiak Sciences44.40%OCSOculisN/AVERAVera Therapeutics15.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIAtai Beckley80368.17 million295.27 millionOptionableKODKodiak Sciences9062.58 million34.79 millionOptionableOCSOculis257.98 millionN/ANot OptionableVERAVera Therapeutics4071.78 million60.37 millionOptionableOCS, KOD, VERA, and ATAI HeadlinesRecent News About These CompaniesJ. Safra Sarasin Holding AG Has $524,000 Stake in Vera Therapeutics, Inc. $VERAJuly 16, 2026 | marketbeat.comVera Therapeutics Inc - Ordinary Shares - Class AJuly 13, 2026 | money.usnews.comAnalysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA), Crinetics Pharmaceuticals (CRNX) and Revolution Medicines (RVMD)July 12, 2026 | theglobeandmail.comCandriam S.C.A. Increases Position in Vera Therapeutics, Inc. $VERAJuly 12, 2026 | marketbeat.comVera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets LaunchJuly 11, 2026 | marketbeat.comVera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% RunJuly 10, 2026 | finance.yahoo.comVera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA ApprovalJuly 10, 2026 | finance.yahoo.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 10, 2026 | globenewswire.comVera Therapeutics (NASDAQ:VERA) Stock Price Down 6.8% on Insider SellingJuly 10, 2026 | marketbeat.comQ3 EPS Forecast for Vera Therapeutics Decreased by AnalystJuly 10, 2026 | marketbeat.comMarshall Fordyce Sells 46,250 Shares of Vera Therapeutics (NASDAQ:VERA) StockJuly 10, 2026 | insidertrades.comVera Therapeutics: A Crowded IgAN Market Leaves No Room For A Premium (Downgrade)July 9, 2026 | seekingalpha.comVera Therapeutics (NASDAQ:VERA) CEO Sells $1,956,375.00 in StockJuly 9, 2026 | marketbeat.comVera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William TurnerJuly 9, 2026 | globenewswire.comVera Therapeutics wins FDA nod for closely watched kidney disease drugJuly 8, 2026 | finance.yahoo.comPharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and moreJuly 8, 2026 | statnews.comSFDA grants accelerated approval to Vera Therapeutics' TrutaknaJuly 8, 2026 | finance.yahoo.comWedbush Issues Positive Forecast for Vera Therapeutics (NASDAQ:VERA) Stock PriceJuly 8, 2026 | marketbeat.comUnder the Radar: Vera Stock Jumps as Kidney-Disease Drug Approved by FDAJuly 7, 2026 | wsj.comFDA approves Vera Therapeutics kidney disease treatmentJuly 7, 2026 | statnews.comSVera Therapeutics wins first FDA approval with kidney disease drugJuly 7, 2026 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026The SpaceX Sell-Off May Be More Than a Market OverreactionBy Jeffrey Neal Johnson | June 24, 2026Rocket Lab's NASA Win Tests Key Support After Sharp PullbackBy Ryan Hasson | June 26, 2026Dividend Increases: From Over 10% Yields to Over 10% Dividend GrowthBy Leo Miller | June 24, 2026Costco’s Secret Growth Engine May Be Running Out of GasBy Dan Schmidt | June 28, 2026OCS, KOD, VERA, and ATAI Company DescriptionsAtai Beckley NASDAQ:ATAI$7.18 +0.04 (+0.56%) Closing price 07/22/2026 04:00 PM EasternExtended Trading$7.16 -0.01 (-0.21%) As of 05:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Kodiak Sciences NASDAQ:KOD$41.92 -0.50 (-1.18%) Closing price 07/22/2026 04:00 PM EasternExtended Trading$41.52 -0.40 (-0.96%) As of 04:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Oculis NASDAQ:OCS$11.43 -0.53 (-4.43%) Closing price 07/22/2026 04:00 PM EasternExtended Trading$11.43 0.00 (0.00%) As of 07/22/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Vera Therapeutics NASDAQ:VERA$36.06 -1.11 (-2.99%) Closing price 07/22/2026 04:00 PM EasternExtended Trading$36.38 +0.32 (+0.89%) As of 04:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robotaxi Mode Engaged: Tesla Starts Monetizing Its Florida Fleet Insider Moves Are Sending Mixed Signals Across the Tech Sector Boxabl Disrupts Housing With A Tiny Float IPO Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Velo3D Forges a New Reality After Its Sharp Stock Sell-Off Why Apple Could Be the Last One Standing in the Tech Wreck Archer and Anduril Put ACHR Stock on a New Defense Flight Path 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
